Original ArticleOriginal Article

Attributable liver cancer deaths and disability-adjusted life years in China and worldwide: profiles and changing trends

Mengdi Cao, Changfa Xia, Maomao Cao, Fan Yang, Xinxin Yan, Siyi He, Shaoli Zhang, Yi Teng, Qianru Li, Nuopei Tan, Jiachen Wang and Wanqing Chen
Cancer Biology & Medicine July 2024, 20240149; DOI: https://doi.org/10.20892/j.issn.2095-3941.2024.0149

References

  1. 1.↵
    2. Bray F,
    3. Laversanne M,
    4. Sung H,
    5. Ferlay J,
    6. Siegel RL,
    7. Soerjomataram I, et al.
    Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024; 74: 229–63.
    OpenUrlCrossRefPubMed
  2. 2.↵
    2. McGlynn KA,
    3. Petrick JL,
    4. London WT.
    Global epidemiology of hepatocellular carcinoma: an emphasis on demographic and regional variability. Clin Liver Dis. 2015; 19: 223–38.
    OpenUrlCrossRefPubMed
  3. 3.↵
    2. Shi JF,
    3. Cao M,
    4. Wang Y,
    5. Bai FZ,
    6. Lei L,
    7. Peng J, et al.
    Is it possible to halve the incidence of liver cancer in China by 2050? Int J Cancer. 2021; 148: 1051–65.
    OpenUrl
  4. 4.↵
    2. Liu Y,
    3. Zheng J,
    4. Hao J,
    5. Wang RR,
    6. Liu X,
    7. Gu P, et al.
    Global burden of primary liver cancer by five etiologies and global prediction by 2035 based on global burden of disease study 2019. Cancer Med. 2022; 11: 1310–23.
    OpenUrl
  5. 5.↵
    2. Valery PC,
    3. Laversanne M,
    4. Clark PJ,
    5. Petrick JL,
    6. McGlynn KA,
    7. Bray F.
    Projections of primary liver cancer to 2030 in 30 countries worldwide. Hepatology. 2018; 67: 600–11.
    OpenUrlCrossRefPubMed
  6. 6.↵
    2. McGlynn KA,
    3. London WT.
    The global epidemiology of hepatocellular carcinoma: present and future. Clin Liver Dis. 2011; 15: 223–43, vii-x.
    OpenUrlCrossRefPubMedWeb of Science
  7. 7.↵
    2. Marengo A,
    3. Rosso C,
    4. Bugianesi E.
    Liver cancer: connections with obesity, fatty liver, and cirrhosis. Annu Rev Med. 2016; 67: 103–17.
    OpenUrlCrossRefPubMed
  8. 8.↵
    2. Singal AG,
    3. Kanwal F,
    4. Llovet JM.
    Global trends in hepatocellular carcinoma epidemiology: implications for screening, prevention and therapy. Nat Rev Clin Oncol. 2023; 20: 864–84.
    OpenUrl
  9. 9.↵
    2. Cao M,
    3. Ding C,
    4. Xia C,
    5. Li H,
    6. Sun D,
    7. He S, et al.
    Attributable deaths of liver cancer in China. Chin J Cancer Res. 2021; 33: 480–9.
    OpenUrl
  10. 10.↵
    2. Rumgay H,
    3. Arnold M,
    4. Ferlay J,
    5. Lesi O,
    6. Cabasag CJ,
    7. Vignat J, et al.
    Global burden of primary liver cancer in 2020 and predictions to 2040. J Hepatol. 2022; 77: 1598–606.
    OpenUrlCrossRef
  11. 11.↵
    2. Rawla P,
    3. Sunkara T,
    4. Muralidharan P,
    5. Raj JP.
    Update in global trends and aetiology of hepatocellular carcinoma. Contemp Oncol (Pozn). 2018; 22: 141–50.
    OpenUrl
  12. 12.↵
    GBD 2019 Demographics Collaborators. Global age-sex-specific fertility, mortality, healthy life expectancy (HALE), and population estimates in 204 countries and territories, 1950-2019: a comprehensive demographic analysis for the Global Burden of Disease Study 2019. Lancet. 2020; 396: 1160–203.
    OpenUrlCrossRefPubMed
  13. 13.↵
    GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020; 396: 1204–22.
    OpenUrlCrossRefPubMed
  14. 14.↵
    GBD 2019 Risk Factors Collaborators. Global burden of 87 risk factors in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020; 396: 1223–49.
    OpenUrlCrossRefPubMed
  15. 15.↵
    2. Zhu RX,
    3. Seto WK,
    4. Lai CL,
    5. Yuen MF.
    Epidemiology of hepatocellular carcinoma in the Asia-Pacific Region. Gut Liver. 2016; 10: 332–9.
    OpenUrlCrossRefPubMed
  16. 16.↵
    2. Chang AY,
    3. Skirbekk VF,
    4. Tyrovolas S,
    5. Kassebaum NJ,
    6. Dieleman JL.
    Measuring population ageing: an analysis of the Global Burden of Disease Study 2017. Lancet Public Health. 2019; 4: e159–67.
    OpenUrlCrossRef
  17. 17.↵
    2. Ju W,
    3. Zheng R,
    4. Zhang S,
    5. Zeng H,
    6. Sun K,
    7. Wang S, et al.
    Cancer statistics in Chinese older people, 2022: current burden, time trends, and comparisons with the US, Japan, and the Republic of Korea. Sci China Life Sci. 2023; 66: 1079–91.
    OpenUrl
  18. 18.↵
    2. Jafri W,
    3. Kamran M.
    Hepatocellular carcinoma in Asia: a challenging situation. Euroasian J Hepatogastroenterol. 2019; 9: 27–33.
    OpenUrl
  19. 19.↵
    2. Liu Z,
    3. Lin C,
    4. Mao X,
    5. Guo C,
    6. Suo C,
    7. Zhu D, et al.
    Changing prevalence of chronic hepatitis B virus infection in China between 1973 and 2021: a systematic literature review and meta-analysis of 3740 studies and 231 million people. Gut. 2023; 72: 2354–63.
    OpenUrlAbstract/FREE Full Text
  20. 20.↵
    2. Roberts H,
    3. Ly KN,
    4. Yin S,
    5. Hughes E,
    6. Teshale E,
    7. Jiles R.
    Prevalence of HBV infection, vaccine-induced immunity, and susceptibility among at-risk populations: US households, 2013-2018. Hepatology. 2021; 74: 2353–65.
    OpenUrl
  21. 21.↵
    2. Liu J,
    3. Liang W,
    4. Jing W,
    5. Liu M.
    Countdown to 2030: eliminating hepatitis B disease, China. Bull World Health Organ. 2019; 97: 230–8.
    OpenUrlPubMed
  22. 22.↵
    2. Cao G,
    3. Jing W,
    4. Liu J,
    5. Liu M.
    Countdown on hepatitis B elimination by 2030: the global burden of liver disease related to hepatitis B and association with socioeconomic status. Hepatol Int. 2022; 16: 1282–96.
    OpenUrl
  23. 23.↵
    2. Iavarone M,
    3. Lampertico P,
    4. Seletti C,
    5. Francesca Donato M,
    6. Ronchi G,
    7. del Ninno E, et al.
    The clinical and pathogenetic significance of estrogen receptor-beta expression in chronic liver diseases and liver carcinoma. Cancer. 2003; 98: 529–34.
    OpenUrlCrossRefPubMed
  24. 24.↵
    2. Tan DJH,
    3. Setiawan VW,
    4. Ng CH,
    5. Lim WH,
    6. Muthiah MD,
    7. Tan EX, et al.
    Global burden of liver cancer in males and females: changing etiological basis and the growing contribution of NASH. Hepatology. 2023; 77: 1150–63.
    OpenUrl
  25. 25.↵
    2. Kasarinaite A,
    3. Sinton M,
    4. Saunders PTK,
    5. Hay DC.
    The influence of sex hormones in liver function and disease. Cells. 2023; 12: 1604.
    OpenUrl
  26. 26.↵
    2. Lee SR,
    3. Lee YH,
    4. Yang H,
    5. Lee HW,
    6. Lee GS,
    7. An BS, et al.
    Sex hormone-binding globulin suppresses NAFLD-triggered hepatocarcinogenesis after menopause. Carcinogenesis. 2019; 40: 1031–41.
    OpenUrl
  27. 27.↵
    2. White DL,
    3. Tavakoli-Tabasi S,
    4. Kuzniarek J,
    5. Pascua R,
    6. Ramsey DJ,
    7. El-Serag HB.
    Higher serum testosterone is associated with increased risk of advanced hepatitis C-related liver disease in males. Hepatology. 2012; 55: 759–68.
    OpenUrlCrossRefPubMedWeb of Science
  28. 28.↵
    2. Janele D,
    3. Lang T,
    4. Capellino S,
    5. Cutolo M,
    6. Da Silva JA,
    7. Straub RH.
    Effects of testosterone, 17beta-estradiol, and downstream estrogens on cytokine secretion from human leukocytes in the presence and absence of cortisol. Ann N Y Acad Sci. 2006; 1069: 168–82.
    OpenUrlCrossRefPubMedWeb of Science
  29. 29.↵
    2. Huang DQ,
    3. Mathurin P,
    4. Cortez-Pinto H,
    5. Loomba R.
    Global epidemiology of alcohol-associated cirrhosis and HCC: trends, projections and risk factors. Nat Rev Gastroenterol Hepatol. 2023; 20: 37–49.
    OpenUrl
  30. 30.↵
    World Health Organization. Global status report on alcohol and health 2018. Geneva. Available from: https://www.who.int/publications/i/item/9789241565639.
  31. 31.↵
    2. Huang DQ,
    3. Singal AG,
    4. Kono Y,
    5. Tan DJH,
    6. El-Serag HB,
    7. Loomba R.
    Changing global epidemiology of liver cancer from 2010 to 2019: NASH is the fastest growing cause of liver cancer. Cell Metab. 2022; 34: 969–77.e962.
    OpenUrl
  32. 32.↵
    2. Friedman SL,
    3. Neuschwander-Tetri BA,
    4. Rinella M,
    5. Sanyal AJ.
    Mechanisms of NAFLD development and therapeutic strategies. Nat Med. 2018; 24: 908–22.
    OpenUrlCrossRefPubMed
  33. 33.↵
    2. Malik VS,
    3. Willet WC,
    4. Hu FB.
    Nearly a decade on - trends, risk factors and policy implications in global obesity. Nat Rev Endocrinol. 2020; 16: 615–6.
    OpenUrl
  34. 34.↵
    2. Balakrishnan M,
    3. Patel P,
    4. Dunn-Valadez S,
    5. Dao C,
    6. Khan V,
    7. Ali H, et al.
    Women have a lower risk of nonalcoholic fatty liver disease but a higher risk of progression vs men: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2021; 19: 61–71.e15.
    OpenUrlPubMed
  35. 35.↵
    2. Wu EM,
    3. Wong LL,
    4. Hernandez BY,
    5. Ji JF,
    6. Jia W,
    7. Kwee SA, et al.
    Gender differences in hepatocellular cancer: disparities in nonalcoholic fatty liver disease/steatohepatitis and liver transplantation. Hepatoma Res. 2018; 4: 66.
    OpenUrl
  36. 36.↵
    2. Chen W,
    3. Xia C,
    4. Zheng R,
    5. Zhou M,
    6. Lin C,
    7. Zeng H, et al.
    Disparities by province, age, and sex in site-specific cancer burden attributable to 23 potentially modifiable risk factors in China: a comparative risk assessment. Lancet Glob Health. 2019; 7: e257–69.
    OpenUrl
  37. 37.↵
    2. Cornelius ME,
    3. Loretan CG,
    4. Jamal A,
    5. Davis Lynn BC,
    6. Mayer M,
    7. Alcantara IC, et al.
    Tobacco product use among adults - United States, 2021. MMWR Morb Mortal Wkly Rep. 2023; 72: 475–83.
    OpenUrlCrossRef
  38. 38.↵
    United States Public Health Service Office of the Surgeon General; National Center for Chronic Disease Prevention and Health Promotion (US) Office on Smoking and Health. Publications and Reports of the Surgeon General. Smoking cessation: a report of the surgeon general. US Department of Health and Human Services; 2020.
  39. 39.↵
    2. Kawaguchi T,
    3. Kohjima M,
    4. Ichikawa T,
    5. Seike M,
    6. Ide Y,
    7. Mizuta T, et al.
    The morbidity and associated risk factors of cancer in chronic liver disease patients with diabetes mellitus: a multicenter field survey. J Gastroenterol. 2015; 50: 333–41.
    OpenUrlCrossRef
  40. 40.↵
    2. Lam EKK,
    3. Batty GD,
    4. Huxley RR,
    5. Martiniuk ALC,
    6. Barzi F,
    7. Lam TH, et al.
    Associations of diabetes mellitus with site-specific cancer mortality in the Asia-Pacific region. Ann Oncol. 2011; 22: 730–8.
    OpenUrlCrossRefPubMedWeb of Science
  41. 41.↵
    2. Cocker F,
    3. Chien Yee K,
    4. Palmer AJ,
    5. de Graaff B.
    Increasing incidence and mortality related to liver cancer in Australia: time to turn the tide. Austr N Z J Public Health. 2019; 43: 267–73.
    OpenUrl
Back to top

In this issue

Print
Download PDF
Email Article
Citation Tools

Jump to section

Keywords